Bancel suggests Moderna could be open to out-licensing if sales struggle

A critical tenet of Moderna’s business so far has been having sole rights over virtually every clinical-stage asset in the pipeline. That soon may change depending on sales moving forward.

“If we have to, we will be open, of course, to partnerships [for] some of those programs,” CEO Stéphane Bancel told analysts on a third-quarter earnings call. Any fervor to out-license some programs is contingent on how sales look, explained Bancel, who didn't expand on which programs are most likely to be up for grabs.